Turdialieva Parvina Faxridin qizi (1), Xolova Zarina Baymuradovna (2)
This study investigates the diagnostic potential of tumor markers for the early detection of oncological risk among women in the Surkhandarya region of Uzbekistan. Oncological diseases remain a leading cause of morbidity and mortality, and early identification is essential for improving treatment outcomes and survival rates. The research focuses on the evaluation of serum biomarkers, including CA-125, CA-15-3, and carcinoembryonic antigen (CEA), as tools for oncological risk assessment and early screening. The results demonstrate that changes in tumor marker levels are associated with hormonal imbalance, family history of malignancy, and other clinically significant risk factors. The study emphasizes the importance of combining laboratory diagnostics with clinical assessment to improve early detection and strengthen preventive healthcare strategies in regional medical practice.
1. Bast, R. C., Jr., Badgwell, D., Lu, Z., et al. (2009). CA125 and the detection of ovarian cancer: a review of the literature. Journal of Ovarian Research, 2(1), 8.
2. Duffy, M. J. (2006). Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clinical Chemistry, 52(3), 456–462.
3. Moore, R. G., Brown, A. K., Miller, M. C., et al. (2008). The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology, 108(2), 402–408.
4. Bast, R. C., Klug, T. L., St. John, E., et al. (1983). A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New England Journal of Medicine, 309(15), 883–887.
5. Lokich, J. J., & Wickerham, D. L. (2003). Tumor markers in clinical oncology: current uses and future perspectives. Oncology, 17(5), 677–686.
6. Jacobs, I., & Bast, R. C., Jr. (1989). The CA 125 tumor-associated antigen: a review of the literature. Human Reproduction, 4(1), 1–12.